GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 145-156 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

From Gila Monster Venom to Dermatology: The History of GLP-1 Receptor Agonists.

Dyson S; Hoenig L; Levell NJ Professor

Jan 1, 2026Clinics in dermatology

2026PubMedSupporting evidence

Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.

Hegaz MG; Aboud MYA; Kamel AII; Naveed MA; Elsayed OG; Sorathia AZ

Jan 1, 2026BMC endocrine disorders

2026PubMedSupporting evidence

Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic review.

Bhandari P; Sideeg A; Elfeki M; Xie C; Singal AK

Jan 1, 2026Metabolism open

2026PubMedSupporting evidence

Glucagon-like peptide-1 receptor agonists as adjunctive therapy in refractory hypertriglyceridemia following recurrent pancreatitis.

Miura D; Nicholls S; Joham AE; Braude M; Tay CT

Jan 1, 2026JCEM case reports

2026PubMedDirectly related

Pharmacological intersections between type 2 diabetes and cancer: metabolic crosstalk, antidiabetic therapies, and clinical implications.

Liu D; Xie D; Che X; Li X; Xu W; Wu G

Jan 1, 2026Pharmacological research

2026PubMedDirectly related

Postmenopausal bleeding associated with semaglutide: a diagnostic challenge.

Prasad S; Parmar V; Sharma A; Kaur N; Kothia D; Bavaria D

Jan 1, 2026JCEM case reports

2026PubMedDirectly related

Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists.

Elatrebi S; Abuyadek R; Abdelbar SMM; Ahmad MS; Ayyad M; Quoritem MA; Abdel Majid RO; Arafat M; Amgad A; Alnagar A

Jan 1, 2026World journal of transplantation

2026PubMedDirectly related

Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists.

Kerr KW; Chang AT; Sulo S; Stutts JT; Panchalingam T; Ryder JR

Jan 1, 2026Childhood obesity (Print)

2026PubMedDirectly related

The Effect of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors Alone and in Combination on AF Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation.

Ramadan A; Doma M; Yazdanpanah MH; Naeem F; Ptaszek LM; Ruskin JN

Jan 1, 2026Heart rhythm

2026PubMedDirectly related

Effectiveness of telehealth versus in-person appointments for the treatment of obesity in a Brazilian public tertiary care center: A randomized controlled trial.

Rocha FRS; Ferreira RS; Janovsky CCPS; Sañudo A; Zanella MT; Carneiro G

Jan 1, 2026Journal of telemedicine and telecare

2026PubMedDirectly related

Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.

Giraldi LV; Andersen JT; Jespersen J; Baden CS; Fonvig CE; Riis T; Dalhoff KP; Holm JC; Fink-Jensen A; Pagsberg AK; Christensen MB; Gade C

Jan 1, 2026BMJ open

2026PubMedSupporting evidence

Do Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-Analysis.

Alves MLM; Moura Costa AODS; Costa JDVM; Ferreira JSN; Porto LLB; Garrido GA; Gonzalez JVP; Tome JOD; Rodrigues LMR; Pereira BA

Jan 1, 2026International journal of spine surgery